Reportlinker Adds World Biological Drugs Market 2011-2021
NEW YORK, April 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
World Biological Drugs Market 2011-2021
http://www.reportlinker.com/p0470101/World-Biological-Drugs-Market-2011-2021.html
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now.
What revenues will biopharmaceutical markets achieve from 2011 to 2021? What gains can leading companies achieve? What sales trends will national markets - developed and developing - show?
Our study answers those questions and many others for biological drugs. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.
We analyse sales of biologics - such as monoclonal antibodies, insulins, erythropoietins and interferons - by class and product. What is the next stage of the biotech revolution in pharma? Our report shows you where the biopharma industry is heading.
The biological drug market is growing faster than the pharmaceutical market overall. Is biotechnological revenue growth sustainable? Our report shows you prospects there.
Our new report also provides an analysis of the biosimilars industry. You will see what will influence the biopharmaceutical industry from 2011 - technologies, policies and competition.
Our interviews in the biopharma field provide broad and deep perspectives on the challenges facing the industry and market this decade. You will see how.
You can assess the pharma biotechnology industry's strengths, weaknesses, trends and prospects from 2011 onwards.
Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.
Analysis and expert opinion to help your work - so you won't be left behind
Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, an R&D review and expert opinion. We include 97 tables and charts and four interviews (shown in the accompanying lists).
World Biological Drugs Market 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
• You will receive hard data for the biological drug industry - especially our revenue forecasts to 2021
• You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where commercial growth will occur
• You will see the revenue prospects for 20 leading products from 2011 to 2021, with discussions of market potential and competition
• You will find revenue prospects for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
• You will learn how the industry can change and adapt from 2011 to 2021, including prospects for biosimilars (follow-on biologics)
• You will assess leading companies in pharma biotechnology, discovering their activities and outlook
• You will investigate competition and opportunities influencing the biologicals industry from 2011 onwards
• You will see what will stimulate and restrain the industry and market from 2011 onwards
• You will review product development, assessing the potential of R&D
• You will analyse opportunities for established companies and those seeking to enter the biologics market
• You will view expert opinion from our survey, including full interview transcripts.
That combination of quantitative and qualitative market analysis sets our report apart. We give you original market predictions, found only in our work.
You can order our new report, receiving the market information you need
Our report can benefit everybody interested in pharmaceutical biotechnology. You will see where the industry is heading, assessing the opportunities, needs and challenges.
You will find answers and trends here. We aim to save you time and aid your decisions. Please order our report now, making sure you don't miss out.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Table of Contents
1. Executive Summary
1.1 Biological Drugs Market Review
1.2 Contents of This Report
1.3 Research and Analysis Methods
2. Overview of the Biological Drugs Market 2011-2021
2.1 The Biological Drugs Market Was Worth over $100bn in 2010
2.2 Market Forecast 2011-2021
2.3 Biological Drugs versus Small Molecules
2.4 Creating Biological Drugs
2.5 Defining the Biotechnology Space
2.6 What is a Biopharmaceutical?
2.7 Vaccines
3. Monoclonal Antibodies Market 2011-2021
3.1 Monoclonal Antibodies in 2009
3.2 The Science of Antibodies
3.3 Murine, Chimeric, Humanised and Fully-Human MAbs
3.4 Prospects for the Monoclonal Antibodies Market
3.5 Top Products in the MAbs Market
3.5.1 Remicade (Johnson & Johnson) 2011-2021
3.5.2 Avastin (Roche) 2011-2021
3.5.3 Rituxan (Roche) 2011-2021
3.5.4 Humira (Abbott) 2011-2021
3.5.5 Herceptin (Roche) 2011-2021
3.5.6 Lucentis (Roche) 2011-2021
3.5.7 Erbitux (Eli Lilly) 2011-2021
3.5.8 Synagis (AstraZeneca) 2011-2021
3.5.9 Tysabri (Biogen Idec) 2011-2021
3.5.10 Xolair (Roche) 2011-2021
4. Therapeutic Proteins Market 2011-2021
4.1 Overall Prospects for Therapeutic Proteins Sector
4.2 Insulin and Insulin Analogues
4.3 Erythropoietins
4.4 Interferons
4.5 Granular-Colony Stimulating Factors (G-CSF)
4.6 Recombinant Coagulation Factors
4.7 Top Products in the Therapeutic Proteins Market
4.7.1 Enbrel (Amgen) 2011-2021
4.7.2 Epogen (Amgen) 2011-2021
4.7.3 Lantus (Sanofi-Aventis) 2011-2021
4.7.4 Neulasta (Amgen) 2011-2021
4.7.5 Aranesp (Amgen) 2011-2021
4.7.6 Avonex (Biogen Idec) 2011-2021
4.7.7 Rebif (Merck Serono) 2011-2021
4.7.8 Advate (Baxter Healthcare) 2011-2021
4.7.9 Humalog (Eli Lilly) 2011-2021
4.7.10 Novorapid (Novo Nordisk) 2011-2021
5. Biosimilars Market 2011-2021
5.1 Forecast for Biosimilars Market, 2011-2021
5.2 Overview of the Biosimilars Market in 2011
5.3 Biosimilar Monoclonal Antibodies
5.4 Biosimilar Insulins
5.5 Biosimilar Erythropoietins
5.6 Biosimilar Interferons
5.7 Biosimilar G-CSF
6. R&D Pipelines for Biological Drugs
6.1 MAbs
6.2 Dalotuzumab (Merck & Co)
6.3 MAb, CCR4 (Amgen)
6.4 MAb, VEGFR-2 (UCB)
6.5 Ramucirumab (Eli Lilly)
6.6 Necitumumab (Eli Lilly)
6.7 Ipilimumab (Bristol-Myers Squibb)
6.8 Tanezumab (Roche)
6.9 Trastuzumab Emtansine (Roche)
6.10 Numax (AstraZeneca)
6.11 Benlysta (Human Genome Sciences/ GSK)
6.12 Ocrelizumab (Roche/ Biogen Idec)
6.13 Denosumab (Amgen)
6.14 Bapineuzumab (Pfizer/ Johnson & Johnson)
6.15 Solanezumab (Eli Lilly)
6.16 Asthma MAb (BioWa)
6.17 Rabies MAb (Crucell/ Merck & Co.)
6.18 Therapeutic Proteins
6.19 Recombinant Human Factor XIII (Novo Nordisk)
6.20 Juvista (Shire)
6.21 Belatacept (Bristol-Myers Squibb)
7. Leading Companies in the Biological Drugs Market
7.1 Roche Controls Nearly a Quarter of the Biological Drugs Market
7.1.1 Roche
7.1.2 Amgen
7.1.3 Johnson & Johnson
7.1.4 Novo Nordisk
7.1.5 Abbott
7.2 Biopharmaceutical M&A
7.2.1 Mega-Mergers
7.2.2 Smaller Acquisitions
7.3 Major Pharma's Emphasis on Biological Drugs
7.3.1 Pfizer
7.3.2 AstraZeneca
7.3.3 Merck & Co.
7.3.4 Novartis
7.3.5 Sanofi-Aventis
7.3.6 Eli Lilly
7.3.7 GlaxoSmithKline
7.3.8 Teva
8. Leading Countries in the Biological Drugs Market
8.1 Leading Biologic Drug National Markets in 2009
8.2 Forecast for National Markets 2011-2021
8.3 The US
8.3.1 The US: Market Forecast 2011-2021
8.4 Europe
8.4.1 Europe: Market Outlook 2011-2021
8.4.2 France: Market Forecast 2011-2021
8.4.3 Germany: Market Forecast 2011-2021
8.4.4 UK: Market Forecast 2011-2021
8.4.5 Italy: Market Forecast 2011-2021
8.4.6 Spain: Market Forecast 2011-2021
8.5 Japan
8.5.1 Japan: Market Forecast 2011-2021
8.6 China
8.6.1 China: Market Forecast 2011-2021
8.7 India
8.7.1 India: Market Forecast 2011-2021
9. Expert Opinion
9.1 Interview with Ronald A. Rader, President, Biotechnology Information Institute
9.1.1 On Defining 'Biopharmaceutical'
9.1.2 On the Future of Biological Drugs
9.1.3 On Lack of Information Resources in the Pharma Industry
9.1.4 On the Regulatory Uncertainty Surrounding Biopharmaceuticals and Biosimilars
9.1.5 On the Potential and the Problems of Biosimilars
9.2 Interview with Dr Janice Reichert, Editor-in-Chief, MAbs
9.2.1 On the Reasons for the Ascendancy of MAbs
9.2.2 On the Current Indications for MAbs
9.2.3 On Antibody-Drug Conjugates and Bispecifics
9.2.4 On Non-Human Antibodies and Alternative Scaffolds
9.2.5 On the Prospects for Biosimilar Antibodies
9.3 Interview with Steven A. Grossman, President, HPS Group, LLC
9.3.1 On the US Biosimilar Industry in the Next Decade
9.3.2 On Different Pathways to Biosimilar Approval
9.3.3 On the Legislation's Effect on Innovative Biological Drugs
9.4 Interview with Dr James DeGiulio, Expert on Patent Applications and Biotechnology Litigation
9.4.1 On the US Biosimilars Pathway
9.4.2 On the Comparison between US and European Biosimilar Markets
9.4.3 On the Challenges for Biosimilars
9.4.4 On the Regulatory Challenges for Innovative Biopharmaceuticals
10. SWOT Analysis of the Biological Drugs Market and Conclusions
10.1 Strengths
10.1.1 The Biological Drugs Market is Well-Established
10.1.2 Biological Products Bring High Revenues for the Industry
10.1.3 Biopharmaceuticals Target Important Therapeutic Areas
10.2 Weaknesses
10.2.1 Biological Drugs Are Costly
10.2.2 The Biologicals Industry is Insufficiently Dynamic?
10.2.3 The Biosimilar Industry - How Will it Affect the Biologics Industry?
10.3 Opportunities
10.3.1 Biosimilars are a Major Growth Opportunity
10.3.2 The Biosimilars Market is Open
10.3.3 Opportunities Remain in the Patented Biopharmaceutical Sector
10.4 Threats
10.4.1 Cost-Cutting Measures May Endanger Biopharmaceutical Growth
10.4.2 There are Outstanding Health Concerns with Some Biological Products
10.4.3 Clearer Regulatory Policy Would Benefit the Biologics Industry
10.5 Concluding Remarks
List of Tables
Table 2.1 Biological Drugs Market, Revenues ($bn), Shares of Overall Pharmaceutical Market, 2009
Table 2.2 Sectors of the Biological Drugs Market, Revenues ($bn), Market Shares (%) 2009
Table 2.3 Global Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 2.4 Global Biological Drugs Market by Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 2.5 Strengths and Weaknesses of Biological Drugs Compared with Small-Molecule Drugs
Table 3.1 Monoclonal Antibodies, Revenues ($bn), 2009
Table 3.2 Monoclonal Antibodies Market by Indication, Revenues ($bn), Market Shares (%), 2009
Table 3.3 Monoclonal Antibodies Market, Revenues ($bn), Annual Growth (%), CAGR (%), Shares of Biological Drug Market (%), 2009-2021
Table 3.4 Remicade Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.5 Avastin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.6 Rituxan Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.7 Humira Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.8 Herceptin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.9 Lucentis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.10 Erbitux Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.11 Synagis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.12 Tysabri Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.13 Xolair Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.1 Therapeutic Proteins Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.2 Insulins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.3 Erythropoietins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.4 Interferons Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.5 G-CSF Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.6 Recombinant Coagulation Factors Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.7 Enbrel, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.8 Epogen, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.9 Lantus, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.10 Neulasta, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.11 Aranesp, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.12 Avonex, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.13 Rebif, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.14 Advate, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.15 Humalog, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.16 NovoRapid, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 5.1 Biosimilars Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), Market Shares (%), Lead Products, 2009
Table 8.1 Top Countries in the Biological Drugs Market, Revenues ($bn), Market Shares (%)
Table 8.2 Regions in the Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.3 US: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.4 European Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.5 France: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.6 Germany: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.7 UK: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.8 Spain: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.9 Italy: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.10 Japan: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.11 China: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.12 India: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 10.1 SWOT Analysis of the Biological Drugs Market, 2011
List of Figures
Figure 2.1 Biological and Non-Biological Drugs Markets, Revenues ($bn), 2009
Figure 2.2 Sectors of the Biological Drugs Industry, Market Shares, 2009
Figure 2.3 Global Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 2.4 Sectors of the Biological Drugs Industry, Market Shares, 2021
Figure 2.5 Global Biological Drugs Market by Sector, Revenues ($bn), 2009-2021
Figure 3.1 Monoclonal Antibodies, Revenues ($bn), Other Biological Drugs Market Revenues ($bn), 2009
Figure 3.2 Monoclonal Antibodies, Revenues ($bn), Total Pharmaceutical Market Revenues ($bn), 2009
Figure 3.3 Monoclonal Antibodies, Indications, Revenues ($bn), 2009
Figure 3.4 Monoclonal Antibodies, Market Revenues ($bn), 2009-2021
Figure 3.5 Remicade Revenues ($bn), 2009-2021
Figure 3.6 Avastin Revenues ($bn), 2009-2021
Figure 3.7 Rituxan Revenues ($bn), 2009-2021
Figure 3.8 Humira Revenues ($bn), 2009-2021
Figure 3.9 Herceptin Revenues ($bn), 2009-2021
Figure 3.10 Lucentis Revenues ($bn), 2009-2021
Figure 3.11 Erbitux Revenues ($bn), 2009-2021
Figure 3.12 Synagis Revenues ($bn), 2009-2021
Figure 3.13 Tysabri Revenues ($bn), 2009-2021
Figure 3.14 Xolair Revenues ($bn), 2009-2021
Figure 4.1 Therapeutic Proteins: Revenues ($bn), 2009-2021
Figure 4.2 Insulins, Revenues ($bn), 2009-2021
Figure 4.3 Erythropoietins, Revenues ($bn), 2009-2021
Figure 4.4 Interferons, Revenues ($bn), 2009-2021
Figure 4.5 G-CSF, Revenues ($bn), 2009-2021
Figure 4.6 Recombinant Coagulation Factors, Revenues ($bn), 2009-2021
Figure 4.7 Enbrel, Revenues ($bn), 2009-2021
Figure 4.8 Epogen, Revenues ($bn), 2009-2021
Figure 4.9 Lantus, Revenues ($bn), 2009-2021
Figure 4.10 Neulasta, Revenues ($bn), 2009-2021
Figure 4.11 Aranesp, Revenues ($bn), 2009-2021
Figure 4.12 Avonex, Revenues ($bn), 2009-2021
Figure 4.13 Rebif, Revenues ($bn), 2009-2021
Figure 4.14 Advate, Revenues ($bn), 2009-2021
Figure 4.15 Humalog, Revenues ($bn), 2009-2021
Figure 4.16 NovoRapid, Revenues ($bn), 2009-2021
Figure 5.1 Biosimilars Sector Revenues ($bn), 2009-2021
Figure 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), 2009
Figure 8.1 Regions in the Biological Drugs Market, Revenues ($bn), 2009
Figure 8.2 US Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.3 European Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.4 France: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.5 Germany: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.6 UK: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.7 Spain: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.8 Italy: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.9 Japan: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.10 China: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.11 India: Biological Drugs Market, Revenues ($bn), 2009-2021
Companies Listed
Abbott Laboratories
Ablynx
Adnexus
Affibody
Alcon
Alkermes
Alnylam
Amerisource Bergen
Amgen
Arrow
Aspreva Pharmaceuticals
AstraZeneca
Athena Neurosciences
Baxter Healthcare
Bayer Schering Pharma
Becton, Dickinson and Company (BD)
Beijing Shuanglu
Berlex
Biocon
Biogen Idec
Biopartners
BioRexis
Biotechnology Information Institute
Bioton
BioWa
Bristol-Myers Squibb
Cambridge Antibody Technology
Celgene
Celltech
Centocor Ortho Biotech
Centyrex
Chugai
Cipla
CJ Corporation
Cougar Biotechnology
Covagen
Crucell Biotechnology
CT Arzneimettel
Daiichi Sankyo
Dainippon Sumitomo
Department of Health and Human Services
Dompé Farmaceutici
Dong-A
Dr. Reddy's Laboratories
Dyax
Eisai
Elan
Eli Lilly
European League Against Rheumatism
European Medicines Agency (EMA/EMEA)
Facet Biotech
Feron
Food and Drug Administration (FDA)
Forest Laboratories
Fovea
Fresenius
Genentech
GeneScience
Genesis Pharma
Genetics Institute
GenMab
Getz Pharma
Gilead Sciences
GlaxoSmithKline
GlycoFi
Halozyme
Haptogen
Hexal
Hoechst Marion Roussel
Hospira
HPS Group, LLC
Hualida Biotech
Human Genome Sciences
ImClone Systems
Immunex
Insmed
Intas Biopharmaceuticals
International Nephrology Network
Jiangsu Walvax Biotech Company
Johnson & Johnson
King
Knoll
Kyowa Hakko Kirin Co.
La Jolla Pharmaceuticals
LG Life Sciences
Lonza Biologics
Lupin Pharma
MAbs
Medarex
Medicare
Medice
MedImmune
Medixion
Megapharm
Merck & Co.
Merck BioVentures
Merck KGaA
Merck Serono
Micromet
Ministry of Health, Labor and Welfare (MHLW)
Mitsubishi Tanabe Pharma
Molecular Partners
Momenta
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Nektar
NICE
Novartis
Novo Nordisk
OPKO Health
Ortho Pharmaceutical Corporation
Peptech
Pfizer
Pharmacoepia
Pieris
Pierre Fabre
Piramal
Procter & Gamble
Qilu
QLT
Regeneron
Reliance Life Sciences
Rinat
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Seattle Genetics
Shantha Biotechnics
Shire
Sidus
Solvay Pharmaceuticals
State Food and Drug Administration
SurModics
Takeda Pharmaceutical Industries
Tanox Biosystems
Targacept
Teva Pharmaceuticals
Tianjin Medical University Cancer Hospital
Tonghua Dongbao
Transkaryotic Therapies
Tufts Center for the Study of Drug Development
UCB
Vical
Wockhardt
Wyeth (now part of Pfizer)
Ypsomed
Zenyaky Kogyo
ZymoGenerics
To order this report:
: World Biological Drugs Market 2011-2021
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article